BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23419026)

  • 1. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
    J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
    Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
    J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
    Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
    Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
    Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.
    Harland AA; Bender AM; Griggs NW; Gao C; Anand JP; Pogozheva ID; Traynor JR; Jutkiewicz EM; Mosberg HI
    J Med Chem; 2016 May; 59(10):4985-98. PubMed ID: 27148755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
    Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
    ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
    Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
    Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
    Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
    Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
    J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The search for opioid analgesics with limited tolerance liability.
    Wtorek K; Piekielna-Ciesielska J; Janecki T; Janecka A
    Peptides; 2020 Aug; 130():170331. PubMed ID: 32497566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore.
    Henry S; Anand JP; Brinkel AC; McMillan DM; Twarozynski JJ; Loo CE; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2021 Jan; 12(1):216-233. PubMed ID: 33346631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
    Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
    J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.
    Li Y; Eans SO; Ganno-Sherwood M; Eliasof A; Houghten RA; McLaughlin JP
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.
    Nastase AF; Anand JP; Bender AM; Montgomery D; Griggs NW; Fernandez TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2019 Apr; 62(8):4193-4203. PubMed ID: 30916966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics.
    McLaughlin JP; Rayala R; Bunnell AJ; Tantak MP; Eans SO; Nefzi K; Ganno ML; Dooley CT; Nefzi A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.
    Ananthan S; Saini SK; Dersch CM; Xu H; McGlinchey N; Giuvelis D; Bilsky EJ; Rothman RB
    J Med Chem; 2012 Oct; 55(19):8350-63. PubMed ID: 23016952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.